133
Views
0
CrossRef citations to date
0
Altmetric
Cancer Pain and Palliative Care

Impact of Patient Subgroups on the Efficacy and Safety of Methylnaltrexone for Opioid-Induced Constipation in Patients with Advanced Illness

ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon
Pages 3529-3543 | Received 02 May 2023, Accepted 25 Sep 2023, Published online: 20 Oct 2023

References

  • Argoff CE. Opioid-induced constipation: a review of health-related quality of life, patient burden, practical clinical considerations, and the impact of peripherally acting μ-opioid receptor antagonists. Clin J Pain. 2020;36(9):716–722. doi:10.1097/AJP.0000000000000852
  • Johnson DA, Argoff CE. Hot topics in primary care: management of opioid-induced constipation. J Fam Pract. 2015;64(12 Suppl):S4–9.
  • Rogers E, Mehta S, Shengelia R, Reid MC. Four strategies for managing opioid-induced side effects in older adults. Clin Geriatr. 2013;21(4):1.
  • Panchal SJ, Muller-Schwefe P, Wurzelmann JI. Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden. Int J Clin Pract. 2007;61(7):1181–1187. doi:10.1111/j.1742-1241.2007.01415.x
  • Iyer S, Davis KL, Candrilli S. Opioid use patterns and health care resource utilization in patients prescribed opioid therapy with and without constipation. Manag Care. 2010;19(3):44–51.
  • Crockett SD, Greer KB, Heidelbaugh JJ, Falck-Ytter Y, Hanson BJ, Sultan S. American Gastroenterological Association Institute guideline on the medical management of opioid-induced constipation. Gastroenterology. 2019;156(1):218–226. doi:10.1053/j.gastro.2018.07.016
  • Relistor (methylnaltrexone bromide) prescribing information; 2018. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021964s019,208271s003lbl.pdf. Accessed: September 12, 2023.
  • Slatkin N, Thomas J, Lipman AG, et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. J Support Oncol. 2009;7(1):39–46.
  • Thomas J, Karver S, Cooney GA, et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med. 2008;358(22):2332–2343. doi:10.1056/NEJMoa0707377
  • Bull J, Wellman CV, Israel RJ, Barrett AC, Paterson C, Forbes WP. Fixed-dose subcutaneous methylnaltrexone in patients with advanced illness and opioid-induced constipation: results of a randomized, placebo-controlled study and open-label extension. J Palliat Med. 2015;18(7):593–600. doi:10.1089/jpm.2014.0362
  • ECOG performance status scale; 2022. Available from: https://ecog-acrin.org/resources/ecog-performance-status. Accessed August 11, 2023.
  • Michna E, Blonsky ER, Schulman S, et al. Subcutaneous methylnaltrexone for treatment of opioid-induced constipation in patients with chronic, nonmalignant pain: a randomized controlled study. J Pain. 2011;12(5):554–562. doi:10.1016/j.jpain.2010.11.008
  • Slatkin NE, Lynn R, Su C, Wang W, Israel RJ. Characterization of abdominal pain during methylnaltrexone treatment of opioid-induced constipation in advanced illness: a post hoc analysis of two clinical trials. J Pain Symptom Manage. 2011;42(5):754–760. doi:10.1016/j.jpainsymman.2011.02.015
  • Chokhavatia S, John ES, Bridgeman MB, Dixit D. Constipation in elderly patients with noncancer pain: focus on opioid-induced constipation. Drugs Aging. 2016;33(8):557–574. doi:10.1007/s40266-016-0381-2
  • Movantik (naloxegol) prescribing information. Wilmington, DE: AstraZeneca Pharmaceuticals; 2020.
  • Kim SJ, Kwon OD, Han EB, et al. Impact of number of medications and age on adherence to antihypertensive medications: a nationwide population-based study. Medicine. 2019;98(49):e17825. doi:10.1097/MD.0000000000017825
  • van den Beuken-van Everdingen MH, Hochstenbach LM, Joosten EA, Tjan-Heijnen VC, Janssen DJ. Update on prevalence of pain in patients with cancer: systematic review and meta-analysis. J Pain Symptom Manage. 2016;51(6):1070–1090.e1079. doi:10.1016/j.jpainsymman.2015.12.340
  • Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg. 2001;182(suppl 5A):11S–18S. doi:10.1016/S0002-9610(01)00782-6
  • Wickham RJ. Managing constipation in adults with cancer. J Adv Pract Oncol. 2017;8(2):149–161.
  • Kumar L, Barker C, Emmanuel A. Opioid-induced constipation: pathophysiology, clinical consequences, and management. Gastroenterol Res Pract. 2014;2014:1–6. doi:10.1155/2014/141737
  • Nee J, Zakari M, Sugarman MA, et al. Efficacy of treatments for opioid-induced constipation: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2018;16(10):1569–1584. doi:10.1016/j.cgh.2018.01.021
  • Chamberlain BH, Rhiner M, Slatkin NE, Stambler N, Israel RJ. Subcutaneous methylnaltrexone for treatment of opioid-induced constipation in cancer versus noncancer patients: an analysis of efficacy and safety variables from two studies. J Pain Res. 2021;14:2687–2697. doi:10.2147/JPR.S312731